Abdulrahman Katib on STORM-PE Results In Favour of Thrombectomy in PE
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
”Despite the modest sample size, STORM-PE is the first RCT showing that mechanical thrombectomy (using a computer-assisted vacuum system) combined with anticoagulation showed superior physiologic outcomes compared with anticoagulation alone in intermediate-high-risk PE.
The primary endpoint was the change in RV/LV ratio at 48 hours.
Which was segnificantly reduced in the mechanical thrombectomy (CAVT) plus anticoagulation arm.
Worth reading!”
Read the full article here.
Article: Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial
Authors: Robert A. Lookstein, Stavros V. Konstantinides, Ido Weinberg, Suhail Y. Dohad, Zachary Rosol, Grzegorz Kopeć, John M. Moriarty, Sahil A. Parikh, Andrew Holden, Richard N. Channick, Braedon McDonald, Khanjan H. Nagarsheth, Kei Yamada, Rachel P. Rosovsky for the STORM-PE Trial Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian